Introduction
Nasopharyngeal carcinoma (NPC) is a highly invasive malignancy that rises from the epithelial lining of the nasopharynx. With an estimated 86,700 new cases and 50,800 deaths in 2012, NPC is viewed as a relatively rarer form of cancer globally. However, in endemic regions, including Southern China and Southeast Asia, the annual incidence rate reached 15-50/100,000. 1 Although early stage NPC can be managed with high cure rate under radiotherapy, 70%-90% of NPC patients, at the time of initial diagnosis, are characterized by cervical nodal metastasis. 2, 3 The prognosis of NPC has improved a lot with the use of radiotherapy and chemotherapy, but for locally advanced and metastatic NPC, the result remains unsatisfactory due to local relapse and distant metastasis. 4 An urgent need exists to identify novel and specific biomarkers that have clinicopathologic and prognostic values in NPC, and hopefully, help to guide the development of new therapeutic regimens.
Transcription factors of the Sox (sex-determining region Y-box protein) protein family, characterized by a conserved high mobility group DNA binding domain, regulate many diverse developmental processes as well as control homeostasis in adult tissues. 5 There were 20 Sox genes identified. Among these, Sox10 gene was the first Sox submit your manuscript | www.dovepress.com
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gene discovered to be involved in neural crest development. It functions by directing the activity of other genes that signal differentiation of neural crest into other cells, so it is essential for the survival of neural crest precursor cells and for proper differentiation of neural crest-derived melanocytes and glia. 6 The association between Sox10 mutation and myelination deficiency in human being's Waardenburg-Hirschsprung syndrome and disruptions of neural crest development has been established. 7 In the last few years, an increasing amount of evidence has revealed that dysfunction and mutations of Sox factors are implicated in several human diseases, including a variety of cancers. These cancer cells are mostly originated in tissues overlapping with their expression pattern during embryonic development. The involvement of Sox10 in human cancer has been almost exclusively in melanomas and some brain tumors.
8 Sox10 activates the expression of microphthalmiaassociated transcription factor, a well-established oncogene in melanoma, and high expression of Sox10 in melanoma has been found to be involved in metastatic potential of melanoma. [9] [10] [11] However, currently, little information has been addressed concerning the association between Sox10 and carcinogenesis and progression of NPC.
In the present study, for the first time, we investigated Sox10 expression in NPC tissue specimens by immunohistochemistry (IHC) analyses. Besides this, through further analyses, we studied the relationship between Sox10 expression and NPC clinical parameters, as well as the value of Sox10 in predicting NPC prognosis.
Patients and methods study patients and treatments
Between May 2004 and July 2005, 105 consecutive patients with undifferentiated nonkeratinizing nasopharyngeal carcinoma NPC in the Department of Radiotherapy, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China, were enrolled retrospectively in this study. The medical ethics committee of Hunan Cancer Hospital approved the present retrieval method of cancer specimens. The criteria are listed as follows: histologically confirmed NPC, age ranging from 17 years to 77 years, managed in accordance with a uniform protocol, enough available tissue, and clinical follow-up. All patients underwent restaging according to the 2007 International Union against Cancer tumor-node-metastasis (TNM) classification. All patients received conventional two-dimensional radiotherapy. Radiotherapy was administered five times a week at a dose of 2 Gy/day. The accumulated dose of radiation ranged between 66 Gy and 78 Gy. In all, 34 patients were treated with boost dose to skull base. Patients did not receive chemotherapy unless metastasis or recurrence occurred. The primary end point was overall survival. Overall survival was defined as the time (in months) from the date of admission to the date of death from any causes or the last follow-up. The follow-up period ended on December 31, 2010, with a median follow-up of 61 months (range 9-80 months).
ihc and evaluation of immunohistochemical staining
Detailed steps for IHC were following the manufacturer's protocol. Briefly, antigen retrieval was performed in citrate buffer (pH 6.0) for 20 minutes using a microwave oven. After blocking in 10% normal blocking serum at room temperature for 10 minutes, slides were incubated with Sox10 antibody (1:200; Santa Cruz Biotechnology Inc., Dallas, TX, USA) at 4°C overnight. Negative (omission of the primary antibody) and positive controls were included according to manufacturer's datasheet of each antibody.
Semiquantitative assessment of the staining, including analysis of both the intensity and percentage of the stained cells, was used. The staining intensity was scored as 0, 1+, 2+, or 3+ corresponding to colorless, buff, brownish yellow, and dark brown, respectively. The percentage of positive stained cells at each intensity was estimated. Final scores ranging from 0 to 300 was calculated by multiplying the intensity and the percentage scores. The cutoff value for Sox10 was chosen based on a measure of heterogeneity using the log-rank test statistical analysis with respect to overall survival. An optimal cutoff value was identified: a staining index of $14 was used to define tumors of high expression and #13, tumors of low expression. statistical analysis SPSS 18.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. The Pearson's chi-squared test was used to determine the correlation between Sox10 expression and clinical factors. Survival curves were plotted using the Kaplan-Meier method and compared with the log-rank test. Statistically significant P-value was set as ,0.05.
Results
sox10 is highly expressed in nPc patients
To determine Sox10 expression in clinical samples, we performed IHC analysis in 105 NPC specimens and adjacent tissues. It was revealed that Sox10 was expressed in 84.8% 
sox10 is associated with clinical aggressiveness in nPc patients
To elaborate the relationship between Sox10 expression levels and clinicopathological characteristics, 105 paraffinembedded NPC tissue specimens were selected for Sox10 IHC staining. A summary of Sox10 expression and clinicopathological parameters is presented in Table 1 . 
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Zhao et al univariate analysis, the overall survival of the NPC patients was correlated with Sox10 expression (P=0.005) and age (P=0.027). Multivariate analysis showed that Sox10 may be viewed as an independent predictor for NPC overall survival (P=0.011; Table 2 ). Kaplan-Meier method and the log-rank test also showed a significantly inverse correlation between high Sox10 expression level and patient overall survival (P=0.004), revealing that higher levels of Sox10 expression were associated with shorter survival rate ( Figure 2) . These results, all together, revealed that Sox10 may be a potential biomarker for the prediction of prognosis of NPC patients receiving radiotherapy.
Discussion
Characterized by a conserved high mobility group DNA binding domain, the Sox family is a group of related transcription factors that have demonstrated their importance in chondrogenesis, hematopoiesis, neural crest development, and neurogenesis. Over the years, continuous studies have revealed that many genes first identified as key genes in cancer development play crucial roles in embryogenesis. Conversely, many of the proteins controlling embryonic development are also involved in carcinogenesis, indicating that both processes are closely related. 12 An increasing number of studies have discovered the association between Sox genes and tumorigenesis in various kinds of malignancies, including glioma, breast cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, and colon rectal cancer. [13] [14] [15] [16] [17] [18] The most thoroughly studied member in this family is Sox2. Luo et al found that Sox2 was highly expressed in NPC compared with the nontumorous tissues. Furthermore, Sox2 correlated significantly with several clinical-pathological factors and epithelial-mesenchymal transition-associated indicators (E-cadherin/N-cadherin and Snail). 19 With regard to Sox10, it was found to exist in various tissues, including heart, lungs, brain, adrenal glands, bladder, pancreas, salivary glands, colon, prostate, and testis in adulthood. The existence of Sox10 in visceral tissues was believed to be attribute to the presence of glial components in the peripheral nervous system in these tissues. 20 Although many studies have discovered the role of Sox10 mainly in melanoma, in salivary gland tumors, and brain tumors, like anaplastic oligodendroglioma, studies focusing on Sox10 in NPC are limited. 8, 21 Our study discovered that Sox10 was highly expressed in NPC tissue, with staining found in both the nucleus and the cytoplasm. This is similar to the result of Sox10 staining in salivary adenoid cystic and breast basal-like carcinomas. 22 We discovered that high expression of Sox10 was correlated with advanced tumor stages and advanced N stage in NPC, which suggests that high expression of Sox10 correlates with locally invasive features. Many studies showed the involvement of Sox10 in tumor aggressiveness. In melanoma, Hoek et al described that high levels of Sox10 have been correlated with a proliferative gene expression signature and low levels are associated with the gene expression profile of a highly invasive phenotype. 23, 24 Hoang et al's 25 research retrospectively studied 428 cases of invasive ductal carcinoma of the breast. A significant association between Sox10 expression and high-grade, estrogen receptor/progesterone receptor-negative, triple-negative, or basal-like invasive ductal carcinoma was discovered. These results may be explained by the mechanism in which Sox10 works. One of the genes that is crucial in regulating the growth, differentiation, and survival of cells of the melanocytic lineage is microphthalmiaassociated transcription factor (MITF). 26 One way that Sox10 works is to act on MITF upstream, activate MITF expression, as well as synergize with MITF to activate downstream targets. 27 Cronin et al's 28 study discovered previously unknown mutations in MITF and Sox10. These mutations added up to .9% in primary melanoma tumors and 22% in metastatic melanoma tumors, which implied the involvement of MITF and Sox10 in melanoma. Using Kaplan-Meier analysis, we discovered that high expression of Sox10 is associated with adverse overall survival and could be used as an independent prognostic marker. Our finding may be explained by the involvement of Sox10 in stem cell marker potential. Sox10 has been viewed as a stem cell marker and is found to be expressed extensively in melanoma. 29 Studies also found that stable Sox10 knockdown in human melanoma cells arrested cell growth, altered cellular morphology and cell cycle, and induced senescence. 30 Apart from in melanoma, 31 Sox10 has also shown its stem cell marker potential in breast cancer. Sox10 was specifically expressed in mammary cells exhibiting the highest levels of stem/progenitor activity. This included fetal and adult mammary cells in vivo and mammary organoids in vitro. Sox10 was functionally relevant, as its deletion reduced stem/progenitor competence, whereas its overexpression increased stem/progenitor activity. 
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Zhao et al Also, as a key downstream effector of Sox9 in the mammary stem cell induction, Sox10 promotes the tumorigenic and metastasis-seeding abilities of human breast cancer cells and is associated with poor patient survival. 31 Tumor stem cells can lead to tumor cell proliferation and resistance to treatment. The mechanism on which Sox10 works on NPC remains to be explored by more work.
However, there are some limitations in our study. First, considering the favorable prognosis of patients diagnosed with NPC, we selected patients from 2004 to 2005 to better evaluate the prognosis. This resulted in incomplete data and inability to analyze progression-free survival because of lack of information in the Province Public Security Bureau and many people changed their phone numbers. Also, no patients included received concurrent chemoradiotherapy since it was not the standard treatment. From another viewpoint, this may better review the relationship between Sox10 expression and radiosensitivity. Second, the number of patients selected was 105. The results would be more convincing if more patients were included.
Next, we are planning to further validate the relationship between Sox10, radiosensitivity, and prognosis in NPC by downregulating (through knockdown) or upregulating Sox10 expression in NPC cell lines.
Conclusion
In summary, we found that Sox10 was highly expressed in NPC and was associated with tumor aggressiveness and prognosis. It may serve as a potential biomarker for NPC patients. Finally, Sox10 may hopefully become a novel therapeutic target for NPC patients.
